BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Etalanetug readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Etalanetug\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06602258-686@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Etalanetug: Phase 2 readout est. (NCT06602258)
DESCRIPTION:Etalanetug\, phase 2\, Alzheimer's Disease.\nStudy: A Study of 
 E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzhe
 imer's Disease\nEstimated primary completion: 3 December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/etalanetug#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06602258
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01760005-686@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Etalanetug: Phase 2/3 readout est. (NCT01760005)
DESCRIPTION:Etalanetug\, phase 2/3\, Alzheimer's Disease.\nStudy: Dominantl
 y Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A
  Study of Potential Disease Modifying Treatments in Individuals at Risk fo
 r or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mu
 tation. Master Protocol DIAN-TU-001\nEstimated primary completion: April 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/etalanetug#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT01760005
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269394-686@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Etalanetug: Phase 2/3 readout est. (NCT05269394)
DESCRIPTION:Etalanetug\, phase 2/3\, Alzheimer's Disease.\nStudy: Dominantl
 y Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A
  Study of Potential Disease Modifying Treatments in Individuals With a Typ
 e of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU
 )\nEstimated primary completion: April 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/etalanetug#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05269394
URL:https://assetmemo.bio/drug/etalanetug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
